Spots Global Cancer Trial Database for tisagenlecleucel
Every month we try and update this database with for tisagenlecleucel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | NCT02529813 | Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients | NCT03876769 | B-Cell Acute Ly... | CTL019 | 1 Year - 25 Years | Novartis | |
| Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma | NCT04234061 | Mantle Cell Lym... | ibrutinib and T... | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia | NCT03628053 | Acute Lymphobla... | Tisagenlecleuce... Blinatumomab Inotuzumab | 18 Years - | Novartis | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | NCT05541341 | Diffuse Large B... Acute Lymphobla... Follicular Lymp... | tisagenlecleuce... | - 100 Years | Novartis | |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | NCT02529813 | Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT05633615 | Diffuse Large B... Grade 3b Follic... Primary Mediast... Recurrent Diffu... Refractory Diff... Transformed Fol... Transformed Mar... | Axicabtagene Ci... Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Lisocabtagene M... Mosunetuzumab Patient Observa... Polatuzumab Ved... Positron Emissi... Tisagenlecleuce... | 18 Years - | SWOG Cancer Research Network | |
| Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel | NCT05541328 | Diffuse Large B... | Tisagenlecleuce... | 18 Years - 99 Years | Novartis | |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | NCT04890236 | Recurrent Diffu... Refractory Diff... | Duvelisib Tisagenlecleuce... | 18 Years - | Emory University | |
| Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients | NCT03876769 | B-Cell Acute Ly... | CTL019 | 1 Year - 25 Years | Novartis | |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | NCT05075603 | Refractory Diff... Refractory Diff... Recurrent Diffu... Refractory High... Refractory Tran... | Efineptakin alf... Tisagenlecleuce... Axicabtagene ci... Lisocabtagene M... | 18 Years - | NeoImmuneTech | |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | NCT04890236 | Recurrent Diffu... Refractory Diff... | Duvelisib Tisagenlecleuce... | 18 Years - | Emory University | |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | NCT05075603 | Refractory Diff... Refractory Diff... Recurrent Diffu... Refractory High... Refractory Tran... | Efineptakin alf... Tisagenlecleuce... Axicabtagene ci... Lisocabtagene M... | 18 Years - | NeoImmuneTech | |
| Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma | NCT03568461 | Follicular Lymp... | tisagenlecleuce... | 18 Years - | Novartis | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel | NCT05541328 | Diffuse Large B... | Tisagenlecleuce... | 18 Years - 99 Years | Novartis | |
| Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma | NCT03570892 | Non-Hodgkin Lym... | Tisagenlecleuce... Platinum-based ... | 18 Years - | Novartis | |
| Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies | NCT06408194 | Leukemia Acute Lymphobla... | CD22CART infusi... Tisagenlecleuce... | 1 Year - 25 Years | Stanford University | |
| Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) | NCT04225676 | Acute Lymphobla... | Tisagenlecleuce... | 2 Years - 25 Years | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
